4 Topic Commentaries

Early-Phase Data Support Novel Contrast Agent

• 

  Benjamin M. Yeh, MD

  Abdominal/Body Imaging, CT and MR contrast materials

  •

  University of California, San Francisco

  We carefully designed this new class of oral contrast agent to overcome many of the diagnostic shortcomings of existing contrast agents for a broad range of diseases.

  Source
• 

  Achille Mileto, MD

  Abdominal Imaging (body CT and abdominopelvic MRI)

  •

  University of Washington School of Medicine

  The novel dark borosilicate contrast agent has the potential to improve the assessment of numerous pathologies, including the detection of cancer and inflammatory disorders.

  Source
• 

  Joel G. Fletcher, MD

  Abdominal Imaging and CT

  •

  Mayo Clinic

  Pathologies within the lumen will be better displayed because the lumen is more distended, and the brightness of the pathologies on the CT images will be increased, making them more conspicuous.

  Source
• 

  Janos L. Tanyi, MD, PhD

  Gynecologic Oncology

  •

  Perelman School of Medicine at the University of Pennsylvania

  This FDA approval offers more precise surgical intervention for patients with ovarian cancer who face a high risk of recurrence after their initial treatment.

  Source